A Canadian survey on the management of corticosteroid induced osteoporosis by rheumatologists

Journal of Rheumatology

Volumn 27, Issue 6, 2000, Pages 1506-1512

  Soucy, Elaine ^a   Bellamy, Nicholas ^a,c   Adachi, Jonathan D ^b   Pope, Janet E ^a   Flynn, Jennifer ^a   Sutton, Eleanor ^d   Campbell, Jane ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d NONE

Author keywords

Corticosteroid; Osteoporosis; Practice pattern; Survey

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; ETIDRONIC ACID;

ARTICLE; BONE DENSITY; CLINICAL PRACTICE; CORTICOSTEROID THERAPY; DRUG INDUCED DISEASE; DUAL ENERGY X RAY ABSORPTIOMETRY; HORMONAL THERAPY; HUMAN; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUESTIONNAIRE;

ADRENAL CORTEX HORMONES; ADULT; ALENDRONATE; BONE DENSITY; CALCITONIN; CANADA; DATA COLLECTION; DENSITOMETRY, X-RAY; ETIDRONIC ACID; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; OSTEOPOROSIS; PHYSICIAN'S PRACTICE PATTERNS; POSTMENOPAUSE; PRACTICE MANAGEMENT, MEDICAL; PREMENOPAUSE; QUESTIONNAIRES; REFERRAL AND CONSULTATION; RHEUMATOLOGY;

EID: 0034084562     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Mitchell DR, Lyles KW. Glucocorticoid-induced osteoporosis: mechanisms for bone loss; evaluation of strategies for prevention. J Gerontol 1990;45:M153-5.
2. Luckert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:35.1-64.
3. Smith R. Corticosteroids and osteoporosis. Thorax 1990;45:537-8.
4. Libanati CR, Baylink DJ. Prevention and treatment of glucocorticoid-induced osteoporosis: a pathogenetic perspective. Chest 1992;102:1426-35.
5. Adachi JD, Bensen WG, Hodsman AB. Corticosteroid-induced osteoporosis. Semin Arthritis Rheum 1993;22:375-84.
6. Hahn TJ. Steroid and drug-induced osteoporosis. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. 2nd edition. New York: Raven Press; 1993:250-5.
7. Olbricht T, Benker G. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment with special regard to the rheumatic diseases. J Intern Med 1993;234:237-44.
8. Reid IR, Grey AB. Corticosteroid osteoporosis. Baillieres Clin Rheumatol 1993;7:573-87.
9. Luckert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994;20:630-51.
10. Joseph JC. Corticosteroid-induced osteoporosis. Am J Hosp Pharm 1994;51:188-97.
11. Sambrook PN, Jones G. Corticosteroid osteoporosis. Br J Rheumatol 1995;34:8-12.
12. Eastell R, on behalf of a UK Consensus Group Meeting on Osteoporosis. Management of corticosteroid-induced osteoporosis. J Intern Med 1995;237:439-47.
13. Lane NE, Mroczkowski PJ, Hochberg MC. Prevention and management of glucocorticoid-induced osteoporosis. Bull Rheum Dis 1995;44:1-4.
14. Dequeker J, Westhovens R. Low dose corticosteroid associated osteoporosis in rheumatoid arthritis and its prophylaxis and treatment: bones of contention. J Rheumatol 1995;22:1013-9.
15. Gulko PS, Mulloy AL. Glucocorticoid-induced osteoporosis: pathogenesis, prevention and treatment. Clin Exp Rheumatol 1996;14:199-206.
16. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-801.
17. Patel S. Current and potential future drug treatment for osteoporosis. Ann Rheum Dis 1996;55:700-14.
18. Miller PD, Bonnick SL, Rosen CJ for the Society for Clinical Densitometry. Clinical utility of bone mass measurements in adults. Consensus of an international panel. Semin Arthritis Rheum 1996;25:361-72.
19. Adinoff AD, Hollister JR. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983;309:265-8.
20. Verstraeten A, Dequeker J. Vertebral and peripheral bone mineral content and fracture incidence in postmenopausal patients with rheumatoid arthritis: effect of low dose corticosteroids. Ann Rheum Dis 1986;45:852-7.
21. Dykman TR, Gluck OS, Murphy WA, Hahn TJ, Hahn BJ. Evaluation of factors associated with glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1985;28:361-8.
22. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991;18:804-8.
23. Michel BA, Bloch DA, Wolfe F, Fries JF. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. J Rheumatol 1993;20:1666-9.
24. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. Ann Rheum Dis 1995;54:49-52.
25. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994;96:115-23.
26. Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol 1996;23:995-1000.
27. Sambrook P, Birmingham J, Kelly P, et al. Prevention of corticosteroid osteoporosis: a comparison of calcium, calcitriol and calcitonin. N Engl J Med 1993;328:1747-52.
28. Diamond T, McGuigan L, Barbagallo S, Bryant C. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in post-menopausal women. Am J Med 1995;98:459-63.
29. Adachi JD, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994;21:1922-6.
30. Struys A, Snelder AA, Mulder H. Cyclic etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis. Am J Med 1995;99:235-42.
31. Reid IR, King AR, Alexander CJ, Ibbertson HK. Prevention of steroid-induced osteoporosis with (3-amino-hydroxypropylidene-1,1-bisphosphonate (APD)). Lancet 1988;1:143-6.
32. Reid IR, Heap SW, King AR, Ibbertson HK. Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis. Lancet 1988;2:1144-5.
33. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997;337:382-7.
34. Adams JS, Wahl TO, Lukert BP. Effects of hydrochlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981;30:217-21.
35. Cauley JA, Cummings SR, Seeley DG, et al. Effects of thiazide diuretic therapy on bone mass, fractures and falls: The Study of Osteoporotic Fractures Research Group. Ann Intern Med 1993;118:666-73.
36. Morton DJ, Barrett-Connor EL, Edelstein SL. Thiazides and bone mineral density in elderly men and women. Am J Epidemiol 1994;139:1107-15.
37. Jones J, Nguyen T, Sambrook PH, Eisman JA. Thiazide diuretics and fractures: can meta-analysis help? J Bone Miner Res 1995;10:106-11.
38. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesteron replacement therapy reduces glucocorticoid-induced bone loss. J Bone Miner Res 1992;7:1063-9.
39. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37:1499-505.
40. Mulder H, Struys A. Intermittent cyclical etidronate in the prevention of corticosteroid-induced bone loss. Br J Rheumatol 1994;33:348-50.
41. Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticosteroid-induced osteoporosis. Eur J Clin Pharmacol 1987;33:35-9.
42. Montemorro L, Schiraldi G, Frioli P, Tosi G, Ribbdi A, Rizzato G. Prevention of corticosteroid-induced osteoporosis with calcitonin in sarcoid patients. Calcif Tissue Int 1991;49:71-6.
43. Healey J, Paget S, Williams-Russo P, et al. Randomized trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80.
44. Adami S, Rossini M. Anabolic steroids in corticoisteroid-induced osteoporosis. Wien Med Wochenschr 1993;44:395-7.
45. Greenwald M, Brandli D, Spector S, Silverman S, Golde G. Corticosteroid-induced osteoporosis: effects of a treatment with slow-release sodium fluoride. Osteoporosis Int 1992;2:203-4.